I am a
Home I AM A Search Login

Papers of the Week

Papers: 2 Jan 2021 - 8 Jan 2021

Human Studies, Pharmacology/Drug Development


2021 Jan 05

Eur J Neurol

Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial.


Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD
Eur J Neurol. 2021 Jan 05.
PMID: 33400330.


Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3-12 months, little is known about long-term therapy.